Search Results
May 31, 2026, 20:00 ET 2026 ASCO | Innovent Presents Long-Term Follow-up Results from the PoC Study of IBI363 (TAK-928) (PD-1/IL-2α-bias bispecific fusion protein), Showing Robust Survival Benefits in Advanced Immunotherapy-Resistant Non-Small Cell Lung Cancer
Ib/II trials are evaluating IBI363 in NSCLC and CRC including the first-line and later line settings, and in additional tumor types. IBI363 has received two Fast Track Designations (FTD) from the U.S. FDA and three Breakthrough Therapy Designations (BTD) from China NMPA so far.In October 2025, Innovent
More news about: Innovent Biologics
May 31, 2026, 20:00 ET 2026 ASCO | Innovent Presents Preliminary PoC Data of IBI363 (TAK-928) PD-1/IL-2α-bias bispecific fusion protein) in First-line Advanced NSCLC
Ib/II trials are evaluating IBI363 in NSCLC and CRC including the first-line and later line settings, and in additional tumor types. IBI363 has received two Fast Track Designations (FTD) from the U.S. FDA and three Breakthrough Therapy Designations (BTD) from China NMPA so far.In October 2025, Innovent
More news about: Innovent Biologics
May 31, 2026, 19:30 ET TiumBio to Present Phase 2a Interim Data Highlighting Differentiated Clinical Profile for Tosposertib(TU2218) plus Pembrolizumab in First-Line R/M HNSCC at ASCO 2026
oral dual inhibitor designed to block the signaling pathways of transforming growth factor-beta (TGF-β) and vascular endothelial growth factor (VEGF), two critical mediators of tumor growth and metastasis. This novel drug candidate was discovered and developed by Tiumbio to enhance the therapeutic efficacy
More news about: TiumBio
May 31, 2026, 14:09 ET EQT sets target fund size for EQT Infrastructure VII at EUR 21 billion
fund's investment strategy is expected to be materially in line with the predecessor fund EQT Infrastructure VI. To ensure continuity between two fund generations, EQT's capital raisings usually follow a cycle with successor funds targeted to be in a position to commence investment activities when
More news about: EQT
May 31, 2026, 12:03 ET iHuman Inc. Announces Acquisition of Businesses and Assets Related to All Knowledge and Perfect Lingo
asset transfer agreements to acquire the businesses and assets related to two products, All Knowledge (全知识) and Perfect Lingo (万词王) (the "Acquisitions"), for an aggregate consideration of RMB94.0 million, subject to potential two-way price adjustments and contingent earn-out payments.
More news about: iHuman Inc.
May 31, 2026, 10:59 ET Kulani Kinis Makes Miami Swim Week Debut with "Endless" Runway Experience and SOJOS Eyewear Collaboration
the room deeper into the shared world of both brands. The collaboration also debuted a six-piece co-branded sunglasses capsule on the runway, across two frame shapes, Sunset and Sunrise, each offered in three colorways."I feel dizzy with the magic we've experienced this evening," said Dani Atkins,
More news about: Kulani Kinis
May 31, 2026, 09:00 ET HARMONi-6 Demonstrates Significant Overall Survival Benefit (HR=0.66): Ivonescimab Plus Chemotherapy Superior to PD-1 Plus Chemotherapy in First-Line sq-NSCLC Landmark Results to Be Presented at ASCO 2026 Plenary Session
metastatic sites and HR=0.69 in those with liver metastases.Comparable subsequent anticancer therapy between the two armsProportions of patients in the two groups who subsequently received immunotherapy: 13.9% in the treatment group vs 19.2% in the control group; proportions receiving
More news about: Akeso, Inc.
May 31, 2026, 08:29 ET RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) pivotal data show strong and durable responses in advanced head and neck cancer where options remain limited
resistanceSubcutaneous amivantamab is designed to dual target both epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition (MET), two pathways associated with tumor growth and resistance, while engaging the immune system.9"Patients with recurrent or metastatic head
More news about: Johnson & Johnson
May 31, 2026, 08:27 ET Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradigm
seizure while receiving ERLEADA and of engaging in any activity where sudden loss of consciousness could cause harm to themselves or others.In two randomized studies (SPARTAN and TITAN), five patients (0.4%) treated with ERLEADA and one patient treated with placebo (0.1%) experienced a seizure.
More news about: Johnson & Johnson
May 31, 2026, 08:00 ET GRAIL Presents PATHFINDER 2 Results of More Than 35,000 Participants Showing the Galleri® Test Substantially Increased Cancer Detection With Robust Performance and Favorable Safety at 2026 ASCO Annual Meeting
than half (53.0%) of the new cancers detected by Galleri were stage I or II, and 71.3% of these have no USPSTF A and B recommended screening. More than two-thirds (70.9%) of the new cancers detected by Galleri were detected at stages I-III, when treatment with curative intent is more often possible."PATHFINDER
More news about: GRAIL, Inc.
May 30, 2026, 22:15 ET SIX FLAGS FIESTA TEXAS UNLEASHES WEREWOLF GORGE, THE WORLD'S LONGEST FAMILY LAUNCH ROLLER COASTER
coaster and the longest roller coaster in park history, Werewolf Gorge stretches an impressive 4,120 feet and delivers an exhilarating two-minute, 36-second adventure, featuring four launches, speeds up to 45 mph and the highest number of floater airtime elements ever incorporated
More news about: Six Flags Entertainment Corporation
May 30, 2026, 20:09 ET Dizal Presents Positive NSCLC Data for Fourth-Generation EGFR TKI DZD6008 and Golidocitinib in Combination with Anti-PD-1 at ASCO 2026
biopharmaceutical company committed to developing novel medicines for the treatment of oncology and hematological diseases, today announced the presentations of two studies in non-small cell lung cancer (NSCLC) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. One study evaluated DZD6008, an
More news about: Dizal Pharmaceutical
May 30, 2026, 20:00 ET Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab for First-Line Treatment of PD-L1-Positive NSCLC Published in The Lancet
been approved and marketed in China for: 1) unresectable locally advanced or metastatic triple‑negative breast cancer (TNBC) who have received at least two prior systemic therapies (at least one of them for advanced or metastatic setting); 2) EGFR mutant-positive locally advanced or metastatic non-squamous
More news about: Kelun-Biotech
May 30, 2026, 14:58 ET Cyient Enters Agreement to Acquire TAO Digital
services rooted in customer centricity enables innovative and transformational outcomes for customers at pace and at scale.TAO Digital brings two synergistic capabilities that are central to Cyient's Intelligent Engineering propositionAI and Data Engineering enabling
More news about: Cyient
May 30, 2026, 14:43 ET Cyient Enters Agreement to Acquire TAO Digital
services rooted in customer centricity enables innovative and transformational outcomes for customers at pace and at scale.TAO Digital brings two synergistic capabilities that are central to Cyient's Intelligent Engineering propositionAI and Data Engineering enabling
More news about: Cyient
May 30, 2026, 11:06 ET MakerWorld's First User-Initiated Charity Contest Names Winners, Bringing Global Creators' Goodwill Directly to Cancer Wards
directly into filament, printers, and production resources, with MakerWorld facilitating delivery to Pascal. Three P1S printers currently sustain the two-week production-to-clinic cadence and are running near full capacity. As donated points convert into additional equipment and materials, that cadence
More news about: Bambu Lab
May 30, 2026, 09:00 ET Cupshe Returns to Miami Swim Week 2026 With "The Arrival" at Temple House
a world rooted in calm, coastal refinement.The collection was structured across two chapters. Chapter I, Daylight Arrival, opened with soft, sunlit resort moments featuring the JoJo Fletcher x Cupshe Drop two collection. Chapter II, Golden Hour Energy, shifted into a more vibrant, socially charged
More news about: Cupshe
May 30, 2026, 08:00 ET GRAIL Reports Full Results From NHS-Galleri Trial Demonstrating Substantial Reduction in Stage IV Cancer Diagnoses at 2026 ASCO Annual Meeting
140,000 asymptomatic participants, aged 50 to 77, and was conducted in partnership with the NHS in England. Participants provided three blood samples over two years, about 12 months apart. The primary objective of the NHS-Galleri trial was to show a reduction in late-stage (III-IV) cancers in people who received
More news about: GRAIL, Inc.
May 30, 2026, 06:36 ET Chandigarh University Research Scientist Receives Startup Research Grant of Rs 24 Lakhs
sustainability-driven research," added Dr Gahlaut.Notably, the Startup Research Grant (SRG) is a two-year scheme designed to help researchersThe Startup Research Grant (SRG) is a two-year funding scheme by the ANRF under the Department of Science and Technology (DST) Government of India
More news about: Chandigarh University
May 30, 2026, 06:00 ET MakerWorld's First User-Initiated Charity Contest Names Winners, Bringing Global Creators' Goodwill Directly to Cancer Wards
directly into filament, printers, and production resources, with MakerWorld facilitating delivery to Pascal. Three P1S printers currently sustain the two-week production-to-clinic cadence and are running near full capacity. As donated points convert into additional equipment and materials, that cadence
More news about: Bambu Lab
May 30, 2026, 04:14 ET Replenish Nutrients: Market Has Yet to Price in the H2 2026 Capacity and Licensing Inflection
a regional fertilizer producer. The combination of a proven proprietary manufacturing process, a capital-light licensing model that has now produced two operating agreements, and meaningful per-tonne carbon savings versus conventional synthetic alternatives — referenced in a third-party study completed
More news about: Replenish Nutrients
May 30, 2026, 01:51 ET Global Times 'Overseas China Week' photo exhibition in Bishkek highlights China-Kyrgyzstan friendship, enhanced SCO cooperation
that she had paid a visit to the city's first waste incineration power plant invested and built by a Chinese enterprise. She observed that since the two countries promoted the construction of waste treatment facilities last year, local environmental sanitation has improved notably, ecological governance
More news about: Global Times
May 29, 2026, 23:32 ET The Results of Phase III OptiTROP-Lung05 Study of Sacituzumab Tirumotecan (sac-TMT) Presented as an ASCO Oral Presentation and Simultaneously Published in The Lancet
been approved and marketed in China for: 1) unresectable locally advanced or metastatic triple‑negative breast cancer (TNBC) who have received at least two prior systemic therapies (at least one of them for advanced or metastatic setting); 2) EGFR mutant-positive locally advanced or metastatic non-squamous
More news about: Kelun-Biotech
May 29, 2026, 22:30 ET Mach Travel Solutions Delivers Sustained FY26 Performance Despite Challenging Macro- Economic Environment; While Accelerating Transformation into an Integrated Travel Solutions Platform
government and institutional projects, spiritual tourism, inbound tourism and technology-enabled travel management solutions.With over two decades of experience, the Company has established strong capabilities in managing large-scale travel programmes, conferences, events and institutional
More news about: Mach Travel Solutions Limited
May 29, 2026, 19:30 ET LAWSUIT FILED ON BEHALF OF CHILD HOSPITALIZED WITH HEMOLYTIC UREMIC SYNDROME IN THE KEBAB SHOP E. COLI OUTBREAK
As of May 19, 2026, nine California residents had been infected with the outbreak strain, including six children. Five people were hospitalized and two developed HUS.On May 24, 2026, FSIS issued a public health alert after beef kofta samples collected from The Kebab Shop tested positive for E.
More news about: Marler Clark, The Food Safety Law Firm